Selection and Characterization of DNA Aptamers Against FokI Nuclease Domain

Maui Nishio; Ayana Yamagishi; Kaori Tsukakoshi; Yoshio Kato; Chikashi Nakamura; Kazunori Ikebukuro

doi:10.1007/978-1-4939-8799-3_12

Selection and Characterization of DNA Aptamers Against FokI Nuclease Domain

Methods Mol Biol. 2018:1867:165-174. doi: 10.1007/978-1-4939-8799-3_12.

Authors

Maui Nishio¹, Ayana Yamagishi², Kaori Tsukakoshi¹, Yoshio Kato², Chikashi Nakamura^{1

2}, Kazunori Ikebukuro³

Affiliations

¹ Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Tokyo, Japan.
² Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan.
³ Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Tokyo, Japan. ikebu@cc.tuat.ac.jp.

PMID: 30155822
DOI: 10.1007/978-1-4939-8799-3_12

Abstract

Genome editing with site-specific nucleases (SSNs) may be effective for gene therapy, as SSNs can modify target genes. However, the main limitation of genome editing for clinical use is off-target effects by excess amounts of SSNs within cells. Therefore, a controlled delivery system for SSNs is necessary. Previously we have reported on a zinc finger nuclease (ZFN) delivery system, which combined DNA aptamers against FokI nuclease domain (FokI) and nanoneedles. Here, we describe how DNA aptamers against FokI were selected and characterized for genome editing applications.

Keywords: Aptamer; FokI nuclease; Genome editing; Nanoneedles.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aptamers, Nucleotide / pharmacology*
Deoxyribonucleases, Type II Site-Specific / antagonists & inhibitors*
Gene Editing / methods*
Genetic Therapy
Genome, Human
HEK293 Cells
Humans
Zinc Finger Nucleases / chemistry*

Substances

Aptamers, Nucleotide
Zinc Finger Nucleases
endodeoxyribonuclease FokI
Deoxyribonucleases, Type II Site-Specific